Marco Meglio

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided commentary on an innovative approach using virtual reality to detect early signs of Parkinson disease.

Using patients with post–COVID-19 neurological symptoms, 90% of the cohort fulfilled the criteria for chronic fatigue syndrome, as expressed by the SOFA scale.

If approved, the oral fixed-dose coformulation of sodium phenylbutyrate-taurursodiol will become the third medication to receive an FDA greenlight for ALS.

In a recently submitted medical device report, Philips reported 14 serious injuries and 0 deaths related to the use of the recalled masks.

The substudy of the COVER-MS Project includes 300 patients with multiple sclerosis and will harness Quest Diagnostic’s national network of more than 2100 patient centers to provide periodic blood samples of immune responses to COVID-19 vaccines.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.

Despite efforts to reduce perioperative complications rates by vetting of surgeons and sites, and refining patient selection, the findings nonetheless demonstrated no clinical benefit from the addition of stenting to medical therapy.

Stringent governmental measures predicted lower global scores on Pittsburgh Sleep Quality Index, while, albeit to a small extent, less restrictive measures were related to worse subjective sleep quality.

Among controls, there was a statistically significant difference of modified Rankin Scale scores between patients with and without atrial fibrillation, whereas no statistical difference was observed in the implantable loop recorder group.

Treatment with rimegepant, an FDA-approved treatment for acute and preventative migraine, resulted in decreases of more than 30% in monthly butalbital prescription fill and reductions of more than 25% in mean milligrams dispensed.

Compared with placebo, vamorolone-treated patients showed significantly better outcomes on several secondary and exploratory end points, such as the NorthStar Ambulatory Assessment and time to climb 4 stairs.

Evening physical activity was associated with lower restless legs syndrome severity, while more time spent in the morning on physical activity, specifically light physical activity, was associated with worse sleep quality.

Using Strong et al’s classification criteria, the percentage of SOD1+ and SOD1- patients with altered cognitive and/or behavioral profiles were similar; however, cognitive and behavioral impairment differentiated between groups.

After switching from idursulfase to Denali’s DNL310, patients demonstrated mean declines of more than 80% for both heparan sulfate and dermatan sulfate biomarkers at week 49 of treatment.

Milvexian at doses of 25 mg to 100 mg twice daily showed an approximate 30% relative risk reduction of ischemic stroke compared with placebo.

Even after adjusting for multiple confounding variables including recognized factors associated with cardiovascular diseases, PTSD plus insomnia remained an independent factor of major adverse cardiovascular events.

In comparison to nonresponders, those in the active treatment group who did respond well exhibited longer disease duration and lower baseline levodopa equivalent dose.

The director of medical outpatient services at the Kennedy Krieger Institute discussed the changes and implications of new CDC guidelines on developmental milestones for growing children.

Younger patients were more likely to have epilepsy-related imaging abnormalities, while older patients were more likely to have incidental abnormalities or those with an unknown relationship to epilepsy.

In a subanalysis of individuals with acute ischemic stroke with tandem lesions, treatment with the Penumbra system resulted in successful revascularization in almost 90% of patients.

Those who had used tobacco at any time demonstrated multiple significantly lower whole-brain measures than nonusers, including total cortical surface area, cortical volume, and total intracranial volume.

Results showed significantly smaller bilaterally gray matter volumes in Parkinson disease compared with controls, but no differences in brain-first or body-first subtypes on asymmetric atrophy.

Plasma GFAP was increased in both presymptomatic and symptomatic mutation carriers compared with noncarriers, and in symptomatic compared with presymptomatic carriers.

For patients with MCA M2 occlusions, use of the Zoom Stroke Solution resulted in significant decreases in National Institutes of Health Stroke Scale scores and no reported perforations or other reperfusion–catheter-related complications.

Between the 2 trials, patients showed significantly lower annualized relapse rates and mean number of gadolinium-enhancing lesions when treated with ublituximab relative to teriflunomide.

The transition period between summer and school represents a key time for children and adolescents to focus on sleep, correct poor sleep habits, and set themselves up for long-term success, both academically and physically.

Branaplam, an mRNA splicing modifier, was being evaluated in a cohort of 75 participants with early manifest Huntington disease, using change in mutant huntingtin protein as the primary outcome measure.

Investigators concluded there were no viable candidates for CVD risk phenotyping in sleep clinics because there were no strong links between any individual or type of oximetry pattern and incident cardiovascular disease.

Treatment with remote ischemic conditioning performed twice daily for 2 weeks as an adjunct to guideline-based treatment resulted in higher odds of modified Rankin Scale scores between 0 and 1, and 0 and 2.

In a multiday ascending dose trial, pharmacokinetic analysis indicated a direct linear relationship between drug dosing concentration and blood plasma levels for each of the 5 days of dosing.